Prostate Specific Antigen Features

CME Articles

PCA3: What Is Its Role in Prostate Cancer Screening?

Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.

The Medical Minute University Offers New Urine Test for Prostate Cancer Screening

University Offers New Urine Test for Prostate Cancer Screening

The University of Michigan Health System is offering a new urine test called Mi-Prostate Score to improve on PSA screening.

The Medical Minute Decision Aids Fail to Change PSA Screening Rates

Decision Aids Fail to Change PSA Screening Rates

Both web-based and print-based decision aids appear to improve patient's informed decision making about prostate cancer screening.

Latest Prostate Specific Antigen News

PSA Nadir in ADT Recipients: The Lower, The Better

PSA Nadir in ADT Recipients: The Lower, The Better

The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.

CTCs Predict Survival in Men with Metastatic CRPC

CTCs Predict Survival in Men with Metastatic CRPC

Higher circulating tumor cell counts are associated with an increased risk of death.

PSA Screening Declining, Especially Among Urologists

PSA Screening Declining, Especially Among Urologists

Trend follows the 2012 release of a U.S. Preventive Services Task Force recommendation against such testing.

Bisphenol A May Boost Prostate Cancer Risk

Bisphenol A May Boost Prostate Cancer Risk

Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.

PSA Levels, Kinetics May Predict PCa Bone Scan Results

PSA Levels, Kinetics May Predict PCa Bone Scan Results

High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.

Added Criteria May Identify Prostate Cancer Surveillance Candidates

Added Criteria May Identify Prostate Cancer Surveillance Candidates

Additional predictors guide selection of patients for active surveillance programs.

Model Predicts PCa Overdiagnosis Risk

Model Predicts PCa Overdiagnosis Risk

New nomogram could help clinicians and patients make treatment decisions.

Transperineal Prostate Biopsy Trumps TRUS

Transperineal Prostate Biopsy Trumps TRUS

TPTPB should be regarded as the gold-standard test in men with two sets of negative TRUS-guided biopsies and rising PSA levels, researchers say.

Primary-Care Physicians Drive PSA Testing for Older Men

Texas study shows that PSA screening was ordered for 41% of men aged 75 and older, largely because of decisions by primary-care physicians.

Prostate Cancer Screening Cost Nearly Half Billion in 2009

Prostate Cancer Screening Cost Nearly Half Billion in 2009

Biopsy-related procedures accounted for much of the cost.

PSADT May Give Wrong Prostate Cancer Prognosis

Relying on PSA doubling time from just one year of active surveillance can result in as many as one in five prostate cancer patients being advised to undergo curative treatment that may be unnecessary.

Short-Term PSA Testing to Calculate PSADT is Error-Prone

One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.

PCa Decision Aids Do Not Sway Men

Print- and Web-based tools presenting the benefits and limitations of PSA testing served to help men resolve their own conflicts.

Elevated PSA Linked to Shiftwork

Findings support the notion of a link with sleep or circadian disruption.

Low-Grade PCa Patients Benefit from Surveillance

Low-Grade PCa Patients Benefit from Surveillance

Post-PSA intro, big drop in advanced-stage cancers but only modest drop in high Gleason score cancers.